Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis (Nasdaq: OCS) announced positive topline results from its Phase 2 ACUITY trial for OCS-05, a neuroprotective therapy candidate for acute optic neuritis. The trial met its primary safety endpoint and achieved statistical significance on key efficacy endpoints. The study demonstrated a 43% improvement in GCIPL thickness and 28% improvement in RNFL thickness with OCS-05 (3mg/kg/day) plus steroid versus placebo at 3 months.
The trial involved 36 randomized patients, with 33 included in the modified intent-to-treat analysis. Visual function improvements showed approximately 18 letters improvement at month 3 and 15 letters at month 6. No drug-related serious adverse events were reported, with headache and acne (10.5% each) being the most common side effects.
OCS-05 has received orphan drug designation from both FDA and EMA, and its IND application has been cleared by the FDA. The company reports approximately $105-110 million in cash and equivalents entering 2025.
On January 4, 2025, Oculis Holding AG announced a significant change in its voting rights structure. The change occurred due to Brunnur vaxtarsjóður slhf distributing its shares in Oculis to its own shareholders. This redistribution of shares represents a major shift in the company's ownership structure.
Oculis has published notifications regarding transactions by individuals with managerial responsibilities. The notifications pertain to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to the company's directors.
The attached documents detail the transactions for two directors:
- Anthony Rosenberg - December 2024
- Arshad Khanani - December 2024
Oculis has announced the vesting of earnout shares and the removal of restrictions on these ordinary shares.
The notifications involve key managerial figures, including Anthony Rosenberg, Riad Sherif, Sylvia Cheung, and Pall Johanesson. Each notification details specific transactions related to these individuals.
The vesting of these shares signifies a notable event for the company and its stakeholders, potentially impacting stock performance due to changes in share availability and managerial ownership.
Oculis has announced a one-time equity incentive award issued to a director for his independent services as a consultant. The notification of this managerial transaction involves Arshad Khanani and was published in November 2024.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the Stifel 2024 Healthcare Conference. The event will take place on November 18-19, 2024, at the Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat on November 18 at 3:35 pm ET. The presentation will be available via live webcast, and the company will conduct one-on-one meetings with investors during the conference. Access to the fireside chat will be provided through Oculis' website under the Investors & Media section.
Oculis Holding AG (Nasdaq: OCS) reported Q3 2024 financial results with cash position of $125.0 million, providing runway into 2H 2026. The company achieved significant enrollment progress in its DIAMOND Phase 3 trials, with ~70% enrolled in DIAMOND-1 and ~40% in DIAMOND-2. Research and development expenses increased to $15.0 million, up from $10.0 million in Q3 2023. The company reported a Q3 net loss of $23.3 million. Key upcoming milestones include OCS-05 Phase 2 ACUITY trial topline results expected in December 2024 and planned NDA submission readiness for OCS-01 in Q1 2025.
Oculis Holding AG (Nasdaq: OCS) announces accelerated patient enrollment for its Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program has made substantial progress, with ~70% of patients enrolled in DIAMOND-1 and ~40% in DIAMOND-2. The company has also expanded its DIAMOND program committees with globally renowned retina experts.
The DIAMOND trials are evaluating the efficacy and safety of OCS-01 eye drops in DME patients. If approved, OCS-01 could potentially transform the treatment paradigm as the first topical eye drop to treat DME. Results from Stage 1 of the program showed significant improvements in visual acuity and clinically meaningful reduction in macular edema for patients treated with OCS-01.
Oculis Holding AG (Nasdaq: OCS) announces accelerated patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND-1 trial has enrolled ~70% of patients, while DIAMOND-2 has enrolled ~40%. The company has also expanded its DIAMOND program committees with globally renowned retina experts.
The DIAMOND program consists of two Phase 3, double-masked, randomized, multi-center trials evaluating the efficacy and safety of OCS-01 eye drops in DME patients. If approved, OCS-01 has the potential to be the first topical eye drop to treat DME, potentially transforming the treatment paradigm.
Dr. Arshad M. Khanani, DIAMOND Program Steering Committee Chairperson, highlighted promising results from Stage 1 of the DIAMOND Phase 3 program, showing significant improvements in visual acuity and clinically meaningful reduction in macular edema for patients treated with OCS-01.
Oculis Holding AG (Nasdaq: OCS) announced that updates on its DIAMOND Phase 3 program for OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop for diabetic macular edema (DME), will be presented at two upcoming events. Dr. David Eichenbaum will present at Innovate Retina, while Dr. Riad Sherif, Oculis' CEO, will present at Eyecelerator 2024.
Both presentations will highlight the robust results from Stage 1 of the DIAMOND program at Week 12 and present the design of Stage 2, which will assess efficacy and safety at Week 52. The ongoing DIAMOND-1 and DIAMOND-2 Phase 3 trials aim to enroll 350 patients each. Additionally, Dr. Sherif will discuss upcoming milestones, including topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis, expected before the end of 2024.
FAQ
What is the current stock price of Oculis Holding (OCS)?
What is the market cap of Oculis Holding (OCS)?
